CONDON DENNIS E
Known title: DirectorCIK: 0001111413
Associated companies
Transaction History
| ESTA | ▲ Buy | Grant | 298 | $14K | 12/31/2024 | View on chart |
| ESTA | ▲ Buy | Grant | 318 | $14K | 9/30/2024 | View on chart |
| ESTA | ▲ Buy | Grant | 314 | $14K | 6/30/2024 | View on chart |
| ESTA | ▲ Buy | Grant | 2,334 | $0 | 5/24/2024 | View on chart |
| ESTA | ▲ Buy | Grant | 294 | $15K | 3/31/2024 | View on chart |
| ESTA | ▲ Buy | Grant | 1,158 | $30K | 12/31/2023 | View on chart |
| ESTA | ▲ Buy | Grant | 2,324 | $0 | 5/24/2023 | View on chart |
| ESTA | ▲ Buy | Grant | 2,345 | $0 | 6/17/2022 | View on chart |
| ESTA | ▲ Buy | Option Exercise | 9,000 | $92K | 3/22/2022 | View on chart |
| ESTA | ▼ Sell | Other | 9,000 | $586K | 3/22/2022 | View on chart |
| ESTA | ▲ Buy | Option Exercise | 9,000 | $92K | 9/10/2021 | View on chart |
| ESTA | ▼ Sell | Open Market | 50 | $4K | 9/10/2021 | View on chart |
| ESTA | ▼ Sell | Open Market | 3,872 | $281K | 9/10/2021 | View on chart |
| ESTA | ▼ Sell | Open Market | 1,843 | $135K | 9/10/2021 | View on chart |
| ESTA | ▼ Sell | Open Market | 2,611 | $194K | 9/10/2021 | View on chart |
| ESTA | ▼ Sell | Open Market | 534 | $40K | 9/10/2021 | View on chart |
| ESTA | ▼ Sell | Open Market | 90 | $7K | 9/10/2021 | View on chart |
AI Market Commentary
AI-generatedAll commentary →Synthesized from recent news and fundamentals/technical data -- not human analyst commentary or trader sentiment.
October 11, 2026
ESTA Receives FDA Approval for New Motiva Implant Sizes
Establishment Labs Holdings received FDA clearance for additional sizes of its Motiva implants, expanding its product lineup. The company also reported its Q2 2026 financial results. This regulatory approval is a key development for the medical device maker, potentially broadening its market reach.
ESTA Receives FDA Approval for New Motiva Implant Sizes. Establishment Labs Holdings received FDA clearance for additional sizes of its Motiva implants, expanding its product lineup. The company also reported its Q2 2026 financial results. This regulatory approval is a key development for the medical device maker, potentially broadening its market reach.